Novo Nordisk A/S, Søborg, Denmark.
Covance Clinical Research Unit Ltd, Leeds, UK.
Diabetes Obes Metab. 2021 Jul;23(7):1594-1603. doi: 10.1111/dom.14373. Epub 2021 Mar 29.
To assess the effects of oral semaglutide on postprandial glucose and lipid metabolism, and gastric emptying, in subjects with type 2 diabetes (T2D).
In this randomized, double-blind, single-centre, crossover trial, subjects with T2D received once-daily oral semaglutide (escalated to 14 mg) followed by placebo, or vice versa, over two consecutive 12-week periods. Glucose and lipid metabolism, and gastric emptying (paracetamol absorption) were assessed before and after two types of standardized meals (standard and/or fat-rich) at the end of each treatment period. The primary endpoint was area under the glucose 0-5-h curve (AUC ) after the standard breakfast.
Fifteen subjects were enrolled (mean age 58.2 years, HbA1c 6.9%, body weight 93.9 kg, diabetes duration 3.1 years; 13 [86.7%] males). Fasting concentrations of glucose were significantly lower, and C-peptide significantly greater, with oral semaglutide versus placebo. Postprandial glucose (AUC ) was significantly lower with oral semaglutide versus placebo (estimated treatment ratio, 0.71; 95% CI, 0.63, 0.81; p < .0001); glucose incremental AUC (iAUC ) and glucagon AUC were also significantly reduced, with similar results after the fat-rich breakfast. Fasting concentrations of triglycerides, very low-density lipoprotein (VLDL) and apolipoprotein B48 (ApoB48) were significantly lower with oral semaglutide versus placebo. AUC for triglycerides, VLDL and ApoB48, and triglycerides iAUC , were significantly reduced after oral semaglutide versus placebo. During the first postprandial hour, gastric emptying was delayed (a 31% decrease in paracetamol AUC ) with oral semaglutide versus placebo. One serious adverse event (acute myocardial infarction) occurred during oral semaglutide treatment.
Oral semaglutide significantly improved fasting and postprandial glucose and lipid metabolism, and delayed gastric emptying.
评估口服司美格鲁肽对 2 型糖尿病(T2D)患者餐后血糖和血脂代谢及胃排空的影响。
在这项随机、双盲、单中心、交叉试验中,T2D 患者接受每日一次口服司美格鲁肽(递增至 14mg),随后是安慰剂,或反之,连续两个 12 周疗程。在每个治疗期结束时,在两种标准餐(标准餐和/或高脂肪餐)前后评估葡萄糖和血脂代谢及胃排空(对乙酰氨基酚吸收)。主要终点是标准早餐后 0-5 小时血糖曲线下面积(AUC)。
共纳入 15 名受试者(平均年龄 58.2 岁,HbA1c 6.9%,体重 93.9kg,糖尿病病程 3.1 年;13 名[86.7%]男性)。与安慰剂相比,口服司美格鲁肽时空腹血糖浓度显著降低,C 肽浓度显著升高。与安慰剂相比,口服司美格鲁肽时餐后血糖(AUC)显著降低(估计治疗比为 0.71;95%CI,0.63,0.81;p<0.0001);餐后血糖增量 AUC(iAUC)和胰高血糖素 AUC 也显著降低,高脂肪早餐后也有类似结果。与安慰剂相比,空腹甘油三酯、极低密度脂蛋白(VLDL)和载脂蛋白 B48(ApoB48)浓度显著降低。与安慰剂相比,口服司美格鲁肽时甘油三酯、VLDL 和 ApoB48 的 AUC 和甘油三酯 iAUC 显著降低。口服司美格鲁肽时,胃排空在第一餐后小时延迟(对乙酰氨基酚 AUC 降低 31%)。口服司美格鲁肽治疗期间发生 1 例严重不良事件(急性心肌梗死)。
口服司美格鲁肽可显著改善空腹和餐后血糖及血脂代谢,并延迟胃排空。